HOME >> BIOLOGY >> NEWS
Doing nature one better: Expanding the genetic code in living mammalian cells

La Jolla, CA Researchers at the Salk Institute for Biological Studies have developed a novel strategy to expand the natural repertoire of 20 amino acids in mammalian cells, including neurons, and successfully inserted tailor-made amino acids into proteins in these cells. In a powerful demonstration of the methods versatility, they then used unnatural amino acids to determine the operating mechanism of the molecular gates that regulate the movement of potassium ions in and out of nerve cells.

In the past, this type of engineering has been mainly restricted to bacteria or in yeast, and it was very challenging to efficiently incorporate unnatural amino acids in mammalian cells. But most biomedical questions have to be studied in the cells of higher organisms and animal models to arrive at meaningful answers, explains Lei Wang, Ph.D., an assistant professor in the Chemical Biology and Proteomics Laboratory, who led the current study published in the July issue of Nature Neuroscience.

The genetic code, which is shared by plants, animals and bacteria, includes 64 codons encoding 20 different amino acids and three stop signals. Being able to expand the code and insert non-natural amino not only greatly enhances researchers' ability and precision, but also provides novel tools for addressing challenging questions insurmountable with conventional means.

We had tried using conventional mutagenesis to introduce mutations into the potassium channel but it didnt give us any answers, says Paul A. Slesinger, Ph.D., an associate professor in the Peptide Biology Laboratory, who collaborated with Wang on the current study. Being able to incorporate bulky unnatural amino acids into living mammalian cells really made all the difference, he adds.

During his graduate studies, Wang pioneered a method to accommodate additional amino acids in bacteria. His approach mimicked the strategy every cell relies on to incorporate conventional amino acids
'"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-4100, ext. 1340
Salk Institute
1-Jul-2007


Page: 1 2 3

Related biology news :

1. Doing it right: New book helps biologists conduct rigorous and reliable research
2. Ecologists work to link kids with nature
3. In nature, proteins sweep up nanoparticles
4. Pesticides choke pathway for nature to produce nitrogen for crops
5. Genomic signatures identify targeted therapies for lung cancer
6. Life-long learning -- nature provides natural inspiration for education
7. New synthetic self-assembling macromolecules mimic nature
8. Researchers untangle nature of regressive evolution in cavefish
9. DNA gives new perspectives to understand the mysteries of nature
10. Manipulating nature: Scientists query wildlife birth-control method
11. Beyond the DNA: Chemical signatures reveal genetic switches in the genome

Post Your Comments:
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
Cached News: